Brokerages Set Outset Medical, Inc. (NASDAQ:OM) Target Price at $10.00

Shares of Outset Medical, Inc. (NASDAQ:OM) have received an average recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research analysts recently weighed in on the company. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st.

Institutional Trading of Outset Medical

A number of hedge funds have recently modified their holdings of the business. BML Capital Management LLC increased its position in Outset Medical by 250.2% in the 1st quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after acquiring an additional 1,359,021 shares in the last quarter. Millennium Management LLC grew its position in shares of Outset Medical by 165.8% during the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after buying an additional 262,874 shares during the period. Ensign Peak Advisors Inc increased its stake in shares of Outset Medical by 71.8% in the 4th quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock valued at $2,078,000 after acquiring an additional 234,082 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Outset Medical by 391.3% in the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after acquiring an additional 176,870 shares during the last quarter. Finally, Alyeska Investment Group L.P. raised its position in shares of Outset Medical by 10.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock valued at $22,798,000 after acquiring an additional 150,000 shares during the period.

Outset Medical Stock Down 1.8%

Shares of NASDAQ OM opened at $3.21 on Monday. Outset Medical has a 12-month low of $3.00 and a 12-month high of $16.16. The company has a current ratio of 5.19, a quick ratio of 4.11 and a debt-to-equity ratio of 1.03. The stock has a market cap of $60.34 million, a PE ratio of -0.78 and a beta of 1.90. The company has a 50-day moving average of $4.29 and a 200 day moving average of $4.18.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The business had revenue of $31.64 million for the quarter, compared to analyst estimates of $28.97 million. Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%. As a group, sell-side analysts predict that Outset Medical will post -3.81 EPS for the current fiscal year.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.